Mercedes E. Gorre, Ph.D.

Affiliations: 
2003 University of California, Los Angeles, Los Angeles, CA 
Area:
Molecular Biology, Oncology, Pharmacology
Google:
"Mercedes Gorre"

Parents

Sign in to add mentor
Charles Sawyers grad student 2003 UCLA
 (Molecular mechanisms of STI571 resistance and disease progression in chronic myelogenous leukemia.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Leder K, Foo J, Skaggs B, et al. (2011) Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. Plos One. 6: e27682
Dawson AJ, Bal S, McTavish B, et al. (2011) Inversion and deletion of 16q22 defined by array CGH, FISH, and RT-PCR in a patient with AML. Cancer Genetics. 204: 344-7
Skaggs BJ, Gorre ME, Ryvkin A, et al. (2006) Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proceedings of the National Academy of Sciences of the United States of America. 103: 19466-71
Huron DR, Gorre ME, Kraker AJ, et al. (2003) A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1267-73
Gorre ME, Ellwood-Yen K, Chiosis G, et al. (2002) BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100: 3041-4
Shah NP, Nicoll JM, Nagar B, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2: 117-25
Roumiantsev S, Shah NP, Gorre ME, et al. (2002) Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of Sciences of the United States of America. 99: 10700-5
Gorre ME, Sawyers CL. (2002) Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Current Opinion in Hematology. 9: 303-7
Gorre ME, Mohammed M, Ellwood K, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (New York, N.Y.). 293: 876-80
See more...